Skip to content
Screener

Staar Surgical STAA Financing Cash Flow

Financing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$100M+31.5%
LENSAR, Inc. logo
LENSAR, Inc.LNSR
-$209K-102%
IAR
Integra LifeSciencesIART
$8.3M-76.5%
Schering-Plough logo
Schering-PloughSGP
$157.76M+215%
Glaukos logo
GlaukosGKOS
$991K-55.9%

Other financials

Income statement

See full
Revenue$93.5M+120%
Gross profit$68.9M+146%
Operating income$8.0M+114%
Net income$5.2M+110%
EPS (diluted)$0.10+109%

Balance sheet

See full
Cash & equivalents$131.9M-23.8%
Total debt$37.3M+1.7%
Total equity$352.4M+0.7%
Total assets$451.1M-1.4%

Cash flow

See full
Operating cash flow-$21.7M-278%
CapEx$443.0K-69.8%
Free cash flow-$22.1M-207%

Valuation

See full
Market cap$1.25B-7.5%
Enterprise value$1.16B-5.7%
P/S4.3×-1.7×

Profitability

See full
Gross margin76.9%+2.9pp
Operating margin-9.1%-3.5pp
Net margin-7.2%-3.0pp
FCF margin-19.6%+55.9pp

Returns & leverage

See full
Return on equity-6%-2.4pp
Debt / equity0.1×0.0×
Current ratio5.1×+0.3×

Where this comes from

Reported directly by Staar Surgical in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Staar Surgical’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0000718937-26-000023
Line itemThree Months Ended / April 3, 2026Three Months Ended / March 28, 2025
Repurchase of employee common stock for taxes withheld(1,867)(1,283)
Proceeds from the exercise of stock options170376
Proceeds from vested restricted and performance stock units41
Net cash used in financing activities(1,693)(948)
Effect of exchange rate changes on cash and cash equivalents(45)286
Increase (decrease) in cash and cash equivalents(21,286)28,955
Cash and cash equivalents, at beginning of the year153,150144,159
Cash and cash equivalents, at end of the period$131,864$173,114

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Staar Surgical's financing cash flow?
Staar Surgical (STAA) reported financing cash flow of -$1.69M in Q1 2026.
How has Staar Surgical's financing cash flow changed year-over-year?
Staar Surgical's financing cash flow decreased by 78.6% year-over-year, from -$948K to -$1.69M.
What is the long-term trend for Staar Surgical's financing cash flow?
Over 3 years (2021 to 2024), Staar Surgical's financing cash flow has grown at a -31.3% compound annual growth rate (CAGR), from $18.01M to $5.83M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Staar Surgical's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude